Section 1045 QSBS Rollover: Selling at 4.5 Years Before Hold Period

Aisha founded Meridian Telemetry, a B2B data-infrastructure company, in March 2021. She owned 68% of the original common stock at incorporation for $680. In September 2025, at 4 years 6 months of hold, a public-company acquirer made an offer she could not refuse. The deal would close in October 2025 at a price that valued her common at $14.2M. Problem: she was 6 months short of the §1202 5-year hold. Her options were to close the deal and pay tax on the full gain, negotiate a 6-month delay, or use the §1045 rollover provision to preserve QSBS eligibility.

Situation

Her stock:

Meridian Telemetry incorporated March 2021 as Delaware C-corp.
She contributed $680 at incorporation for 6,800,000 shares at $0.0001.
Series Seed raised 4 months later at $2.5M post-money.
Series A in 2023 at $28M post-money.
2025 acquisition offer: $20M total consideration, of which her share is $14.2M.

Her hold period: March 2021 to October 2025 = 4 years and 7 months. She needs 5 years for §1202.

Her gain at close: $14.2M - $680 = $14.1999M.

Tax impact without §1202 or §1045:

Federal long-term capital gains: 20% × $14.2M = $2.84M.
NIIT: 3.8% × $14.2M = $539k.
Texas: no state income tax.
Total: $3.38M.

Tax impact with full §1202 at 5-year hold (if she had waited):

$10M excluded.
$4.2M taxable at 23.8% federal = $999k.
Savings vs. non-QSBS: $2.38M.

IRC §1045 offers a rollover. If QSBS is sold before 5 years, the gain can be deferred by reinvesting into replacement QSBS within 60 days. The holding period of the original stock tacks to the replacement. Upon eventual sale of the replacement QSBS, §1202 exclusion applies based on the combined holding period.

§1045 requires:

Original stock was QSBS meeting all §1202 requirements.
Replacement stock is also QSBS.
Reinvestment within 60 days of the original sale.
Election made on the tax return for the year of sale (Form 8949 with appropriate code).

What we modeled

Three paths:

Path A: Close the deal, pay the tax.

$3.38M federal tax.
Net proceeds: $10.82M.
No QSBS benefit.
Clean, simple, done.

Path B: Negotiate 6-month delay to reach 5-year hold.

Buyer signals willingness but wants a $500k price reduction for the delay.
Net deal value to Aisha: $13.7M (vs. $14.2M immediate).
At close, $10M excluded under §1202.
Remaining $3.7M taxable at 23.8% = $881k.
Net proceeds: $12.82M.
Savings vs. Path A: $2.0M.

Path C: Close now, use §1045 to roll gain.

Receive $14.2M in October 2025.
Within 60 days (by mid-December 2025), reinvest the gain portion ($14.1999M) into qualifying replacement QSBS.
Deferred gain is recognized only when the replacement QSBS is sold.
Holding period from original Meridian stock tacks, so replacement stock already has 4.5 years of tacked holding period at purchase.
If replacement QSBS is held for any additional period, total hold exceeds 5 years and qualifies for full §1202 treatment on eventual sale.

Path C was interesting but fraught. She needed to find qualifying replacement QSBS within 60 days. Options:

Make a direct investment in a private C-corp (the company must be a qualifying small business at issuance with gross assets under $50M).
Fund a new startup herself.
Participate in a QSBS-eligible secondary (rare, most secondaries involve already-held stock not newly-issued).
Anchor an angel or pre-seed round in a qualifying C-corp.

The 60-day window made path C practical only if she already had QSBS-eligible opportunities lined up.

What she did

She took Path B, the delayed close. The $500k price reduction was annoying but preserved $1.5M of tax savings net. She used the 6 months to put Meridian in “caretaker mode” and help the buyer prepare for integration. Closing happened in April 2026, at which point she had held for 5 years 1 month. She claimed $10M §1202 exclusion and paid tax only on the remaining $3.7M of gain.

But the Path C modeling was not wasted. She had a 10% cushion of stock that she had gifted to an irrevocable non-grantor trust in 2024 as part of QSBS stacking. That trust held 650,000 shares that would receive their own $10M cap. The trust, however, was not party to the delayed-close negotiation; it sold its Meridian stock at the October 2025 date.

The trust’s gain: approximately $1.35M. At just under 5 years of hold, the trust did not qualify for §1202 without §1045. The trust elected §1045 and reinvested the gain into a pre-seed round in a qualifying C-corp that was actively raising within the 60-day window (a connection Aisha had through her angel-investor network). The trust now holds qualifying replacement QSBS with a tacked holding period.

What she wishes she had done differently

She did not incorporate Meridian a month earlier. Meridian’s March 15 incorporation date meant the 5-year clock ran to March 15, 2026. If she had incorporated in February 2021, her clock would have been over by February 2026, which would have saved 6 weeks of negotiating delay. This is a minor point but illustrative: founders should consider QSBS clock timing when choosing incorporation dates.

She also did not do QSBS stacking until 2024. If she had gifted 10-15% of her shares into non-grantor trusts in 2021-2022, when Meridian’s valuation was lower, her gift tax exemption usage would have been minimal and each trust would have preserved its own $10M exclusion cap. At a seed-stage $5M post-money, 15% of the company was worth only $750k. Gifting that to four trusts would have created 4 × $10M = $40M of §1202 exclusion capacity for her family at minimal gift-tax cost. Instead, she gifted at 2024 prices and used much more of her exemption.

Third regret: she did not maintain §1045 “ready to deploy” reserves. Having a network of pre-seed rounds she could quickly invest in, and a qualified-small-business diligence checklist, would have made Path C more viable. Her 2025 §1045 reinvestment through the trust worked because she happened to have a friend raising at the right time. Had that opportunity not existed, the trust would have been stuck with a gain and no §1045 cover.

Fourth: she did not think about the post-OBBBA 2025 QSBS rules. Stock acquired after July 4, 2025 is subject to a $15M per-issuer cap. Her replacement QSBS (through the trust) was acquired December 2025, so it qualifies for the new $15M cap on eventual sale. She should think about this when positioning the trust to hold long-term.

Frequently asked

What is §1045?

IRC §1045 allows rollover of gain from sale of QSBS held less than 5 years into replacement QSBS purchased within 60 days. The election defers the gain, tacks the holding period, and preserves the §1202 benefit on the eventual sale.

How strict is the 60-day window?

Absolute. Reinvestment must close within 60 days of the original sale. Wire transfer of subscription proceeds must be complete. Pre-committing to an investment that closes on day 61 does not qualify.

Can I roll into any QSBS?

The replacement must itself meet all §1202 requirements: domestic C-corp, gross assets under $50M at issuance, active qualified trade or business. Most venture-backed early-stage companies qualify.

What if I reinvest less than the full gain?

Partial rollover is allowed. The unrecovered portion of the gain is taxable currently, and only the reinvested portion benefits from the rollover.

Does §1045 also apply to partnership interests?

§1045 applies only to QSBS. Partnership interests do not qualify. Separate rollover rules exist for partnerships but with different mechanics.

Composite scenario drawn from common patterns in our advisor network's casework. Names, companies, and exact numbers are illustrative. Not tax, legal, or investment advice.